Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

Imatinib is a promising candidate for the treatment of fibrotic diseases. This retrospective study evaluated the use of imatinib for the treatment of refractory sclerotic chronic graft-versus-host disease in 14 patients with different hematologic malignancies. Imatinib was started at a median of 44...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Magro, Leonardo, Mohty, Mohamad, Catteau, Benoit, Coiteux, Valérie, Chevallier, Patrice, Terriou, Louis, Jouet, Jean-Pierre, Yakoub-Agha, Ibrahim
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2009
Konular:
Transplantation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5162701/
https://ncbi.nlm.nih.gov/pubmed/19289852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-02-204750
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller